SYGNIS completes integration of acquired companies’ products and services under Expedeon brand name (news with additional features)

DGAP-News: SYGNIS AG / Key word(s): Miscellaneous

06.03.2018 / 07:30

The issuer is solely responsible for the content of this announcement.


PRESS RELEASE
6 March 2018

SYGNIS completes integration of acquired companies’ products and services under Expedeon brand name

Innova Biosciences, Expedeon Holdings, and C.B.S. Scientific now fully integrated and operating under the Expedeon brand name, effective 1 March 2018

– Strong sales and marketing team unified in SYGNIS’ existing facilities in Cambridge, UK

– Expedeon’s combined offering comprises complementary products and services spanning the complete customer workflow in genomics and proteomics

Heidelberg, Germany and Cambridge, UK, 6 March 2018 SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announced its subsidiaries Innova Biosciences, Expedeon Holdings, and C.B.S. Scientific have united as Expedeon, effective 1 March 2018. The corporate rebranding follows the latest acquisition of Innova Biosciences by SYGNIS AG in June 2017. SYGNIS AG will continue to serve as the parent company and legal entity.

The corporate integration under the Expedeon brand name enables all organisations to take advantage of broad international sales and distribution networks, as well as in-house expertise and e-commerce channels. Customers will benefit from a larger sales footprint, service and support personnel in North America, Europe and Asia. Expedeon serves the genomic, proteomic and immunology research markets, which represent an opportunity approaching $ 100 billion worldwide. The SYGNIS Group has laboratory facilities and commercial sites in the UK, USA, Singapore, Germany and Spain, and a highly skilled workforce of over 100 employees worldwide.

Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, said: “The successful execution of our ‘Grow, Buy and Build strategy’ has significantly enhanced our existing product portfolio, as well as our sales and marketing capacities. With the corporate rebranding, we bring together the Group of companies as Expedeon, in line with our vision to establish our position as a global brand for innovative reagents and services in the life sciences and diagnostics industries. The full integration of the Group supports this vision, and we are excited to continue moving the Company forward.”

The combined Expedeon product portfolio now comprises a wide range of complementary products and services to support the genomic, proteomic and immunology markets. As a fully integrated Company, Expedeon will continue to work toward increasing its market share with a growing range of cutting-edge tools and services to further benefit the research community worldwide. The combined product offering is accessible via the newly launched website www.expedeon.com.

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG (Investor Relations and International Media Relations)
Dr. Claudia Gutjahr-Löser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

Zyme Communications (Trade and UK Media Relations)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About SYGNIS AG: www.sygnis.com
SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group’s cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS’ products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon brand. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=QSBQENMWGR
Document title: Sygnis_Rebrand_to_Expedeon


06.03.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SYGNIS AG
Waldhofer Str. 102
69123 Heidelberg
Germany
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@sygnis.com
Internet: www.sygnis.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this